Paediatric chinese medicine sales list came out, these three drugs annual sales of more than 500 million yuan!

Pharmaceutical Network Industry Dynamic) Recently, CDE released the Technical Guidelines for Real World Evidence supporting the Development and Review of Children's Drugs (Draft for Comments), which apply to all types of children's medicines, including chemicals, Traditional Chinese medicines and biological productsIn this regard, the industry believes that the children's drug market or usher in a positiveit is understood that children's medication refers to a class of drugs suitable for children's special physical fitness and needs design, especially for the use of special hospital pediatricdrugsAt present, the main types of pediatric drugs include: anti-infective drugs, respiratory diseases, digestive diseases, vitamins and other nutritional drugs,anti-heat analgesic s
in and nervous system drugs, generally according to chemical drugs, traditional Chinese medicine, biopharmaceuticals (mainly vaccines) to dividein fact, the increase in the demand for pediatric drugs in recent years is driving the expansion of the size of the pediatric drug market in ChinaData show that in 2019, China's public medical institutions terminal sales of traditional medicine pediatric drugs nearly 9 billion yuan, an increase of 11.61 percent year-on-yearIn the top 20 products, 18 sales exceeded 100 million yuan, one more than in 2018Among them, it is worth noting that in the first 20 pediatric traditional medicine products, there are 3 products sales have reached more than 500 million yuanchildren's hot particles sales: 14.76 (billion yuan)children's hot particles are the main varieties of Jichuan pharmaceutical industry, from the old Chinese medicine Li Shaochuan practice of more than 50 years of experience, with "heat relief, not easy to rebound" characteristics, with heat, anti-inflammatory, antibacterial, anti-viral, anti-viral, gastrointestinal conditioning, protection of the spleen and lung effectAccording to the data, in recent years, the pediatric sage hot particles in China's public medical institutions terminal in the pharmaceutical pediatric drug market has been the top, sales in 2018 exceeded 1 billion, in 2019 reached a new high of 1,476 million yuan, an increase of 21.96 percent year-on-yearJichuan Pharmaceuticals is a high-tech enterprise group that concentrates on Western medicine, Chinese medicine makeup, manufacturing, trade and circulationAt present, with more than 10 dosage forms, more than 210 specifications of the national drug quasi-size product group, there are more than 110 product regulations included in the national medical insurance catalog, there are 68 product regulations into the national basic drug catalog, access to the national invention patent authorization 38 pieces More than 10 varieties of Pudi blue, amel blue, Sichuan, etc are domestic core varieties, core dosage forms, high-tech products in Jiangsu Province and brand-name products in Jiangsu Province Jinzhen oral liquid sales: 5.62 (billion yuan) JinZhen oral liquid is the main product sold by Kangyuan Pharmaceuticals, sales in recent years rose rapidly According to Kangyuan Pharmaceuticals' 2019 report, sales of JinZhen oral liquid increased significantly during the reporting period In 2019Q4, revenue and home-to-home profit was 130 million, up 25.9% YoY Benefiting from the new national health insurance catalog, Jinzhen oral liquid continued to release rapidly, driving faster revenue and performance growth, in 2019, Jinzhen oral liquid sales increased by 32% year-on-year, the growth trend is expected to continue in the future In recent years, Kangyuan Pharmaceuticals has been continuously increasing its investment in research and development, based on traditional Chinese medicine, and actively layout the field of innovative medicines In the future, the company will also focus on the research and development of modern Chinese medicine as the core, continue to increase investment in chemical innovation drug research and development throat sword spray (child type) sales: 5.12 (billion yuan) open throat sword spray children's type, is the core variety of Guizhou Sanli Pharmaceutical, is currently mainly used in the treatment of children's throat disease, with the role of swelling, pain relief, antiviral At present, it has been included in the national health insurance catalog varieties, but also has entered Guizhou, Guangxi, Guangdong, Zhejiang and other local basic drugs directory public information shows that from 2016 to 2018 and the first half of 2019, the total sales revenue of Sanli Pharmaceutical laryngeal sword spray (children's type) and laryngean spray spray was 488 million yuan, 612 million yuan, 693 million yuan and 336 million yuan, respectively, accounting for 94.91 percent, 95.80 percent, 95.89 percent and 96.66 percent of the main business income, respectively.